| 1. |
- Lantuejoul, Sylvie, et al.
(författare)
-
PD-L1 Testing for Lung Cancer in 2019 : Perspective From the IASLC Pathology Committee
- 2020
-
Ingår i: Journal of Thoracic Oncology. - : Elsevier BV. - 1556-0864 .- 1556-1380. ; 15:4, s. 499-519
-
Forskningsöversikt (refereegranskat)abstract
- The recent development of immune checkpoint inhibitors (ICIs) has led to promising advances in the treatment of patients with NSCLC and SCLC with advanced or metastatic disease. Most ICIs target programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) axis with the aim of restoring antitumor immunity. Multiple clinical trials for ICIs have evaluated a predictive value of PD-L1 protein expression in tumor cells and tumor-infiltrating immune cells (ICs) by immunohistochemistry (IHC), for which different assays with specific IHC platforms were applied. Of those, some PD-L1 IHC assays have been validated for the prescription of the corresponding agent for first- or second-line treatment. However, not all laboratories are equipped with the dedicated platforms, and many laboratories have set up in-house or laboratory-developed tests that are more affordable than the generally expensive clinical trial-validated assays. Although PD-L1 IHC test is now deployed in most pathology laboratories, its appropriate implementation and interpretation are critical as a predictive biomarker and can be challenging owing to the multiple antibody clones and platforms or assays available and given the typically small size of samples provided. Because many articles have been published since the issue of the IASLC Atlas of PD-L1 Immunohistochemistry Testing in Lung Cancer, this review by the IASLC Pathology Committee provides updates on the indications of ICIs for lung cancer in 2019 and discusses important considerations on preanalytical, analytical, and postanalytical aspects of PD-L1 IHC testing, including specimen type, validation of assays, external quality assurance, and training.
|
|
| 2. |
- Lin, Zongxing, et al.
(författare)
-
Using Photonic Crystal Microrings to Mitigate Raman-Kerr Effects Competition for Soliton Microcomb Generation
- 2024
-
Ingår i: Journal of Lightwave Technology. - : Institute of Electrical and Electronics Engineers (IEEE). - 0733-8724 .- 1558-2213. ; 42:1, s. 268-275
-
Tidskriftsartikel (refereegranskat)abstract
- In nonlinear microresonators with strong stimulated Raman scattering effect, it is difficult if not impossible to generate Kerr soliton microcombs with a small free spectral range (FSR) (< 100 GHz) due to the competition between the Raman and Kerr effects. In this article, we overcome this limitation by using odd-period photonic crystal microrings (PCMs). Numerical simulations on the silicon-on-insulator (SOI) PCM show that a small frequency shift (5 GHz) induced by the photonic crystal structure can moderately suppress the Raman effect, such that chaotic microcombs with a small FSR can be generated. With a larger frequency shift (e.g., >= 10 GHz), the Raman effect is significantly suppressed, and the soliton microcombs can be generated. For comparison, without the frequency shift, only Raman lasing can be achieved in a conventional microring. To investigate the applicability of the proposed method in other material platforms, we carried out simulations for the aluminium nitride (AlN) PCM. The results are comparable to those obtained on the SOI PCM. Our method opens a new approach to the generation of small FSR Kerr soliton microcombs in microresonators with strong Raman effect, which is important for expanding the available nonlinear platforms and applications such as telecommunications, radio-frequency photonics, and astronomical spectrographs.
|
|
| 3. |
- Mino-Kenudson, Mari, et al.
(författare)
-
The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC
- 2021
-
Ingår i: Journal of Thoracic Oncology. - : Elsevier. - 1556-0864 .- 1556-1380. ; 16:4, s. 686-696
-
Tidskriftsartikel (refereegranskat)abstract
- Introduction: Programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) is required to determine the eligibility for pembrolizumab monotherapy in advanced NSCLC worldwide and for several other indications depending on the country. Four assays have been approved/Communaute Europeene-In vitro Diagnostic (CV-IVD)-marked, but PD-L1 IHC seems diversely implemented across regions and laboratories with the application of laboratory-developed tests (LDTs).Method: To assess the practice of PD-L1 IHC and identify issues and disparities, the International Association for the Study of Lung Cancer Pathology Committee conducted a global survey for pathologists from January to May 2019, comprising multiple questions on preanalytical, analytical, and postanalytical conditions.Result: A total of 344 pathologists from 64 countries participated with 41% from Europe, 24% from North America, and 18% from Asia. Besides biopsies and resections, cellblocks were used by 75% of the participants and smears by 11%. The clone 22C3 was most often used (69%) followed by SP263 (51%). They were applied as an LDT by 40% and 30% of the users, respectively, and 76% of the participants developed at least one LDT. Half of the participants reported a turnaround time of less than or equal to 2 days, whereas 13% reported that of greater than or equal to 5 days. In addition, quality assurance (QA), formal training for scoring, and standardized reporting were not implemented by 18%, 16%, and 14% of the participants, respectively.Conclusions: Heterogeneity in PD-L1 testing is marked across regions and laboratories in terms of antibody clones, IHC assays, samples, turnaround times, and QA measures. The lack of QA, formal training, and standardized reporting stated by a considerable minority identifies a need for additional QA measures and training opportunities.
|
|
| 4. |
- Moreira, Andre L., et al.
(författare)
-
A Grading System for Invasive Pulmonary Adenocarcinoma : A Proposal From the International Association for the Study of Lung Cancer Pathology Committee
- 2020
-
Ingår i: Journal of Thoracic Oncology. - : ELSEVIER SCIENCE INC. - 1556-0864 .- 1556-1380. ; 15:10, s. 1599-1610
-
Tidskriftsartikel (refereegranskat)abstract
- Introduction: A grading system for pulmonary adenocarcinoma has not been established. The International Association for the Study of Lung Cancer pathology panel evaluated a set of histologic criteria associated with prognosis aimed at establishing a grading system for invasive pulmonary adenocarcinoma. Methods: A multi-institutional study involving multiple cohorts of invasive pulmonary adenocarcinomas was conducted. A cohort of 284 stage I pulmonary adenocarcinomas was used as a training set to identify histologic features associated with patient outcomes (recurrence-free survival [RFS] and overall survival [OS]). Receiver operating characteristic curve analysis was used to select the best model, which was validated (n = 212) and tested (n = 300, including stage I-III) in independent cohorts. Reproducibility of the model was assessed using kappa statistics. Results: The best model (area under the receiver operating characteristic curve [AUC] = 0.749 for RFS and 0.787 for OS) was composed of a combination of predominant plus high-grade histologic pattern with a cutoff of 20% for the latter. The model consists of the following: grade 1, lepidic predominant tumor; grade 2, acinar or papillary predominant tumor, both with no or less than 20% of high-grade patterns; and grade 3, any tumor with 20% or more of high-grade patterns (solid, micropapillary, or complex gland). Similar results were seen in the validation (AUC = 0.732 for RFS and 0.787 for OS) and test cohorts (AUC = 0.690 for RFS and 0.743 for OS), confirming the predictive value of the model. Interobserver reproducibility revealed good agreement (k = 0.617). Conclusions: A grading system based on the predominant and high-grade patterns is practical and prognostic for invasive pulmonary adenocarcinoma. (C) 2020 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
|
|
| 5. |
- Sholl, Lynette, et al.
(författare)
-
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker : A Perspective from the International Association for the Study of Lung Cancer Pathology Committee
- 2020
-
Ingår i: Journal of Thoracic Oncology. - : ELSEVIER SCIENCE INC. - 1556-0864 .- 1556-1380. ; 15:9, s. 1409-1424
-
Forskningsöversikt (refereegranskat)abstract
- Immune checkpoint inhibitor (ICI) therapies have revolutionized the management of patients with NSCLC and have led to unprecedented improvements in response rates and survival in a subset of patients with this fatal disease. However, the available therapies work only for a minority of patients, are associated with substantial societal cost, and may lead to considerable immune-related adverse events. Therefore, patient selection must be optimized through the use of relevant biomarkers. Programmed death-ligand 1 protein expression by immunohistochemistry is widely used today for the selection of programmed cell death protein 1 inhibitor therapy in patients with NSCLC; however, this approach lacks robust sensitivity and specificity for predicting response. Tumor mutation burden (TMB), or the number of somatic mutations derived from next-generation sequencing techniques, has been widely explored as an alternative or complementary biomarker for response to ICIs. In theory, a higher TMB increases the probability of tumor neoantigen production and therefore, the likelihood of immune recognition and tumor cell killing. Although TMB alone is a simplistic surrogate of this complex interplay, it is a quantitative variable that can be relatively readily measured using currently available sequencing techniques. A large number of clinical trials and retrospective analyses, employing both tumor and blood-based sequencing tools, have evaluated the performance of TMB as a predictive biomarker, and in many cases reveal a correlation between high TMB and ICI response rates and progression-free survival. Many challenges remain before the implementation of TMB as a biomarker in clinical practice. These include the following: (1) identification of therapies whose response is best informed by TMB status; (2) robust definition of a predictive TMB cut point; (3) acceptable sequencing panel size and design; and (4) the need for robust technical and informatic rigor to generate precise and accurate TMB measurements across different laboratories. Finally, effective prediction of response to ICI therapy will likely require integration of TMB with a host of other potential biomarkers, including tumor genomic driver alterations, tumor-immune milieu, and other features of the host immune system. This perspective piece will review the current clinical evidence for TMB as a biomarker and address the technical sequencing considerations and ongoing challenges in the use of TMB in routine practice. (c) 2020 Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.
|
|
| 6. |
- Yang, Fangkai, et al.
(författare)
-
Diffusion-Based Time Series Data Imputation for Cloud Failure Prediction at Microsoft 365
- 2023
-
Ingår i: ESEC/FSE 2023 - Proceedings of the 31st ACM Joint Meeting European Software Engineering Conference and Symposium on the Foundations of Software Engineering. - : Association for Computing Machinery (ACM). ; , s. 2050-2055
-
Konferensbidrag (refereegranskat)abstract
- Ensuring reliability in large-scale cloud systems like Microsoft 365 is crucial. Cloud failures, such as disk and node failure, threaten service reliability, causing service interruptions and financial loss. Existing works focus on failure prediction and proactively taking action before failures happen. However, they suffer from poor data quality, like data missing in model training and prediction, which limits performance. In this paper, we focus on enhancing data quality through data imputation by the proposed Diffusion+, a sample-efficient diffusion model, to impute the missing data efficiently conditioned on the observed data. Experiments with industrial datasets and application practice show that our model contributes to improving the performance of downstream failure prediction.
|
|
| 7. |
- Yao, Mingguang, et al.
(författare)
-
Synthesis and characterization of SWCNTs with Ho/Ni as catalyst
- 2006
-
Ingår i: New Carbon Materials. - 1007-8827. ; 21:1, s. 70-74
-
Tidskriftsartikel (refereegranskat)abstract
- SWCNTs were synthesized with high yield by DC arc discharge using Ho/Ni as catalysts. The morphologies, diameter distribution and the content of SWCNTs in the products were characterized by SEM, Raman scattering and TGA. Results indicate that SWCNTs can be efficiently synthesized with Ho/Ni as catalysts. The volume content of SWCNTs in a "web-like" form is as high as 80% in the product. Furthermore, the diameter distribution of SWCNTs, estimated by analyzing the resonance Raman scattering using excitation wavelengths of 632 and 488nm, varies from 1.35 to 1.69nm with a dominant diameter of 1.5nm, which is different from that of the SWCNTs synthesized with Ce/Ni as catalyst, proving that the diameter distribution of SWCNTs is dependent on the properties of the metal catalysts.
|
|
| 8. |
- Yu, Miao, et al.
(författare)
-
SERS study of single-walled carbon nanotubes on silver films deposited on different substrates
- 2003
-
Ingår i: Chemical Journal of Chinese Universities / Gao Deng Xue Xiao Hua Xue Xue Bao. - : Chinese Electronic Periodical Services. - 0251-0790. ; 24:6, s. 1285-1288
-
Tidskriftsartikel (refereegranskat)abstract
- Surface-enhanced Raman scattering of single-walled carbon nanotubes (SWNTs) on silver films deposited on various substrates, including sapphire, quartz and glass, has been studied systematically. The characteristic features of G-band and D-band have been analyzed and compared with arc discharged and laser ablation samples. D-band is much more sensitive than G-band. The position and the intensity of the G-band in SERS spectra depend on substrates. The peak shift and absolute intensity of G-band on sapphire is obviously larger than that on glass. The contribution of high frequency vibrations to the D-band is also deendent on substrates. Compared to the SWNTs samples with a high semiconducting tube concentration, the sample with high metallic tube concentration has a stronger interaction with silver films.
|
|
